Results 21 to 30 of about 159,423 (276)

Immune checkpoints in circulating and tumor-Infiltrating CD4 + T Cell Subsets in Colorectal cancer patients [PDF]

, 2019
Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach; however, it has shown limited success in some cancers including colorectal cancer (CRC). The tumor microenvironment (TME) is largely responsible for response to therapy,
Abu Nada, M, Al-Dhaheri, M, Elkord, E, Khawar, M, Murshed, K, Toor, SM   +5 more
core   +2 more sources

Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions.

PLoS Pathogens, 2012
T-cell immune responses modulated by T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) during Mycobacterium tuberculosis (Mtb) infection in humans remain poorly understood.
Yueqin Qiu, Jianbo Chen, Hongying Liao, Yan Zhang, Hua Wang, Shaoyuan Li, Yanfen Luo, Danyun Fang, Guobao Li, Boping Zhou, Ling Shen, Crystal Y Chen, Dan Huang, Jiye Cai, Kaiyuan Cao, Lifang Jiang, Gucheng Zeng, Zheng W Chen   +17 more
doaj   +1 more source

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

The Journal of Clinical Investigation, 2022
T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) negatively regulates innate and adaptive immunity in cancer. To identify the mechanisms of Tim-3 in cancer immunity, we evaluated the effects of Tim-3 blockade in human and mouse melanoma ...
Ornella Pagliano, Robert M. Morrison, Joe-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding, Tokiyoshi Tanegashima, Wentao Gao, Saranya R. Chakka, Richelle DeBlasio, Ava Lowin, Kevin Kara, Mignane Ka, Bochra Zidi, Rada Amin, Itay Raphael, Shuowen Zhang, Simon C. Watkins, Cindy Sander, John M. Kirkwood, Marcus Bosenberg, Ana C. Anderson, Vijay K. Kuchroo, Lawrence P. Kane, Alan J. Korman, Arvind Rajpal, Sean M. West, Minhua Han, Christine Bee, Xiaodi Deng, Xiao Min Schebye, Pavel Strop, Hassane M. Zarour   +32 more
doaj   +1 more source

The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells [PDF]

, 2016
The immune receptor Tim-3 is often highly expressed in human acute myeloid leukemia (AML) cells where it acts as a growth factor and inflammatory receptor.
Bardelli, Marco, Berger, Steffen M., Fasler-Kan, Elizaveta, Fruehwirth, Alexander, Gibbs, Bernhard F., Gonçalves Silva, Isabel, Rüegg, Laura, Sumbayev, Vadim V., Varani, Luca   +8 more
core   +1 more source

TIM-3 Regulates Distinct Functions in Macrophages [PDF]

Frontiers in Immunology, 2016
The transmembrane protein TIM-3 is a type I protein expressed by sub-types of lymphoid cells, such as lymphocytes Th1, Th17, Tc1, NK, as well as in myeloid cells. Scientific evidence indicates that this molecule acts as a negative regulator of T lymphocyte activation and that its expression is modified in viral infections or autoimmune diseases.
Ocaña-Guzman, Ranferi, Torre-Bouscoulet, Luis, Sada-Ovalle, Isabel   +2 more
openaire   +2 more sources

Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. [PDF]

, 2017
Blockade of inhibitory receptors (IRs) overexpressed by T cells can activate antitumor immune responses, resulting in the most promising therapeutic approaches, particularly in bladder cancer, currently able to extend patient survival.
Bohner, P., Cesson, V., Chevalier, M.F., Dartiguenave, F., De Leval, L., Derré, L., Gharbi, D., Gourmaud, J., Jichlinski, P., Legris, A.S., Lhermitte, B., Martin, V., Nardelli-Haefliger, D., Nobile, A., Pieraerts, C., Rotman, S., Speiser, D.E.   +16 more
core   +1 more source

TIM-3 pathway dysregulation and targeting in cancer [PDF]

Expert Review of Anticancer Therapy, 2021
Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancies, but challenges such as limited response ...
Amer M, Zeidan, Rami S, Komrokji, Andrew M, Brunner   +2 more
openaire   +2 more sources

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma

Journal of Immunology Research, 2020
Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies.
Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang   +16 more
doaj   +1 more source

Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection [PDF]

, 2014
More than a decade after West Nile virus (WNV) entered North America, and despite a significant increase in reported cases during the 2012 and 2013 seasons, no treatment or vaccine for humans is available.
Busch, Michael P, Chew, Glen M, Diamond, Michael S, Inglis, Heather C, Lanteri, Marion C, Law, Jacqueline P, Ndhlovu, Lishomwa C, Norris, Philip J, Wong, Derek, Wu, Shiquan   +9 more
core   +3 more sources

Tim-3, Lag-3, and TIGIT [PDF]

, 2017
Co-inhibitory receptors play a key role in regulating T cell responses and maintaining immune homeostasis. Their inhibitory function prevents autoimmune responses but also restricts the ability of T cells to mount effective immune responses against tumors or persistent pathogens.
Joller, Nicole, Kuchroo, Vijay K.
openaire   +3 more sources